scispace - formally typeset
F

Fatih Kocabas

Researcher at Yeditepe University

Publications -  51
Citations -  2278

Fatih Kocabas is an academic researcher from Yeditepe University. The author has contributed to research in topics: Stem cell & Haematopoiesis. The author has an hindex of 13, co-authored 44 publications receiving 1856 citations. Previous affiliations of Fatih Kocabas include University of Texas Southwestern Medical Center & North American University.

Papers
More filters
Journal ArticleDOI

The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche

TL;DR: It is shown that LT-HSCs utilize glycolysis instead of mitochondrial oxidative phosphorylation to meet their energy demands and that Meis1 regulates HSC metabolism through transcriptional activation of Hif-1alpha.
Journal ArticleDOI

Meis1 regulates postnatal cardiomyocyte cell cycle arrest

TL;DR: It is shown that Meis1 is required for transcriptional activation of the synergistic CDK inhibitors p15, p16 and p21, and is a potential therapeutic target for heart regeneration.
Journal ArticleDOI

Meis1 regulates the metabolic phenotype and oxidant defense of hematopoietic stem cells

TL;DR: It is demonstrated here that loss of Meis1 results in down-regulation of both Hif-1α and H if-2α in HSCs, which resulted in a shift to mitochondrial metabolism, increased reactive oxygen species production, and apoptosis of H SCs.
Journal ArticleDOI

Mitochondrial metabolism in hematopoietic stem cells requires functional FOXO3.

TL;DR: The transcription factor FOXO3 is identified as a new regulator of metabolic adaptation of HSC and its findings have critical implications for mechanisms that promote malignant transformation and aging of blood stem and progenitor cells.
Journal ArticleDOI

Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymer complexation in human cancer cells.

TL;DR: A synergism was found between curcumin and paclitaxel, particularly when complexed with PCDT on A2780, SKOV-3, and H1299 cancer cell lines, and a novel drug nanocarrier system was formulated by encapsulating curcuming and pac litaxel in poly(β-cyclodextrin triazine) (PCDT).